SCHEMBL1348833

SCHEMBL1348833

COc1ccc(C(=O)c2ccc(OC)cc2O)c(O)c1.O=C(c1ccc(O)cc1O)c1ccc(O)cc1O

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.89
RAB9A P51151 2/20 0.89
CYP3A4 P08684 6/20 0.75
HPGD P15428 5/20 0.75
LMNA P02545 4/20 0.75
CYP2C19 P33261 3/20 0.75
CYP1A2 P05177 2/20 0.75
PGR P06401 2/20 0.75
SLC6A2 P23975 2/20 0.75
ALOX15 P16050 2/20 0.75
ADORA3 P0DMS8 1/20 0.75
AR P10275 1/20 0.75
CHRM1 P11229 1/20 0.75
TBXA2R P21731 1/20 0.75
ADRA1A P35348 1/20 0.75
HIF1A Q16665 1/20 0.75
ALDH1A1 P00352 4/20 0.68
MAPK1 P28482 4/20 0.68
CYP2D6 P10635 1/20 0.68
PDE4A P27815 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93206 1.00 NPC1 (0.89) NPC1RAB9ACYP3A4HPGDLMNA
SCHEMBL30900821 1.00 NPC1 (0.89) NPC1RAB9ACYP3A4HPGDLMNA
SCHEMBL29419872 1.00 NPC1 (0.89) NPC1RAB9ACYP3A4HPGDLMNA
SCHEMBL1514997 0.94 NPC1 (1.00) NPC1RAB9ACYP3A4HPGDLMNA
SCHEMBL29365072 0.94 NPC1 (1.00) NPC1RAB9ACYP3A4HPGDLMNA
SCHEMBL38652 0.94 NPC1 (1.00) NPC1RAB9ACYP3A4HPGDLMNA
SCHEMBL10453973 0.92 NPC1 (0.96) NPC1RAB9ACYP3A4HPGDLMNA
SCHEMBL29380756 0.92 NPC1 (0.96) NPC1RAB9ACYP3A4HPGDLMNA
SCHEMBL2526579 0.92 NPC1 (0.96) NPC1RAB9ACYP3A4HPGDLMNA
Dioxybenzone SCHEMBL5011376 0.92 HPGD (0.91) NPC1RAB9ACYP3A4HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
US-8063097-B2 Compositions and methods for regulating mammalian keratinous tissue THE PROCTER & GAMBLE COMPANY (US) 2011-11-22 US disclosed
EP-2076274-A2 TOPICAL FORMULATIONS OF TELLURIUM-CONTAINING COMPOUNDS Biomas Ltd. (IL) 2009-07-08 EP disclosed
WO-2008032227-A2 TOPICAL FORMULATIONS OF TELLURIUM-CONTAINING COMPOUNDS BIOMAS, LTD. (IL) 2008-03-20 WO disclosed
US-20080045479-A1 Compositions and methods for regulating mammalian keratinous tissue THE PROCTER & GAMBLE COMPANY 2008-02-21 US disclosed
EP-1622582-A1 COMPOSITIONS AND METHODS FOR REGULATING MAMMALIAN KERATINOUS TISSUE THE PROCTER & GAMBLE COMPANY (US) 2006-02-08 EP disclosed
WO-2004093841-A1 COMPOSITIONS AND METHODS FOR REGULATING MAMMALIAN KERATINOUS TISSUE THE PROCTER & GAMBLE COMPANY (US) 2004-11-04 WO disclosed
US-5073371-A Cationic surfactant, acrylic acid polymer, humectant RICHARDSON-VICKS, INC. (US) 1991-12-17 US disclosed
US-5073372-A Comprising a cationic surfactant, a nonvolatile polysiloxane, a carboxy-containing polymer, a humectant and carrier; fat-free; anionic surfactant-free; acne RICHARDSON-VICKS, INC. (US) 1991-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB NPC1 105/4885RAB9A 1281/4885CYP3A4 3571/4885
US-20080045479-A1 Compositions and methods for regulating mammalian keratinous tissue KRT18, HKDC1, KRTCAP2 NPC1 2224/4885RAB9A 2352/4885CYP3A4 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.